Navigation Links
PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average
Date:10/16/2008

tial new drug application submissions," said Gadi Saarony, Corporate Vice President and Worldwide Head, PAREXEL Consulting. "More than ever, biopharmaceutical companies should focus on reaping the greatest return on their R&D investments, maximizing product value at every stage of the lifecycle, and gaining the most efficiency from the development process. Crucial decisions must be made early in development planning, including which regulatory approaches to apply to achieve first-cycle approval."

"With continuing focus on first-cycle approvals for new drugs, especially under FDA Good Review Management Practices, our goal was to provide biopharmaceutical companies with a real-world metric on the value of first-cycle approvals," said Mark Mathieu, Director of Strategic Research at PAREXEL Consulting. "Our data show that priority designations are now closely linked to first-cycle approvals for both NMEs and NDAs. As a result, this metric can help biopharmaceutical companies assess the value of the new priority review vouchers available under the FDA Amendments Act."

The Getting to Approval white paper is part of PAREXEL Consulting's Intelligent Development Series, which provides data and insights in support of successful biopharmaceutical and medical device product development. The white paper is available at http://www.PAREXELConsulting.com/firstcycleapproval.

About PAREXEL Consulting

PAREXEL Consulting is a leading life sciences consultancy that helps companies design and execute their biopharmaceutical and medical device product strategies through our unique fusion of scientific, regulatory, and business expertise. Our approach helps clients manage risk, and drives superior quality and performance for clients worldwide. The firm has more than 270 experts, and serves clients on a global basis. For further information visit:

SOURCE PAREXEL International
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL International to Present at William Blair Small-Cap Growth Stock Conference
2. PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors
3. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
4. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
5. PAREXEL Closes the Acquisition of ClinPhone
6. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
7. PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer
8. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
9. PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day
10. PAREXEL Expands Global Clinical Logistics Capabilities
11. Parexel Invites Public to Listen to Live Webcast of Its Investor Day June 25, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Guggenheim Securities, ... Partners, today announced the hiring of veteran equity analyst ... equity analyst. Mr. Butler will focus on the biotech/biopharma ... team a wealth of experience and a broad network ... , Senior Managing Director and Head of Equities at ...
(Date:8/27/2014)... 27, 2014 Flagship Biosciences LLC, a ... to the pharmaceutical and medical device industries, has announced ... fast growing company has consolidated its histology and tissue ... to Westminster, CO, just north of Denver. The ... W. 103rd Ave., Suite 100, Westminster, CO 80021 , ...
(Date:8/27/2014)... , Aug. 27, 2014 Research ... "Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014" ... Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 ... state of the global isotope ratio mass spectrometer industry. ... the industry including definitions, classifications, applications and industry chain ...
(Date:8/27/2014)... Tris Pharma, a specialty pharmaceutical company focused ... it has been selected as an award winner in ... Awards for Excellence competition in the Business Expansion ... judges from SCORE (Counselors to America,s Small Business) and ... at a gala event to be held on October ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Flagship Biosciences Announces Relocation and Expansion 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2
... Spherix Incorporated (Nasdaq: SPEX ), an ... and atherosclerosis; and providers of technical and regulatory consulting ... announced the close of previously reported agreements to sell ... Preferred Stock and warrants to purchase shares of its ...
... Agreement on Molecular Tests... -- GERMANTOWN, Maryland and DES PLAINES, Illinois, October 12, 2010, ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... 12 US Oncology, Inc., the nation,s ... enrolled the 1,000th patient in a Phase I clinical ... Phase I clinical trials present special challenges, including increased ... trial designs, and some first-in-human trials, making Phase I ...
Cached Biology Technology:Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 2Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 3QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 2QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 3QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 4QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 5QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 6QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 7QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 8QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 9QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 10US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 2US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 4US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 5
(Date:8/28/2014)... pose a significant health risk to people with asthma according ... Allergy and Clinical Immunology . , By critically reviewing the ... has found that the presence of several types of mould ... as increasing the likelihood of developing the condition. , The ... of Exeter Medical School and is the first time all ...
(Date:8/28/2014)... assigned a number of 435-million-year-old fossils to a ... in shallow marine habitats and were far less ... , Before they sank to the bottom ... some 435 million years ago, these arthropods preyed ... although they were not exactly inconspicuous, possessing a ...
(Date:8/27/2014)... bears, giant ground sloths, saber-toothed cats and American camels ... at the end of the Pleistocene period. The cause ... scientists who, until recently, could only speculate as to ... Barbara,s James Kennett, professor emeritus in the Department of ... played a major role in the extinction. Their hypothesis ...
Breaking Biology News(10 mins):Indoor mold poses health risk to asthma sufferers 2Paleontology: Oldest representative of a weird arthropod group 2Nanodiamonds are forever 2Nanodiamonds are forever 3
... News headlines are filled with discussion and ... Change Conference in Copenhagen. As expected, the ... has focused on traditional environmental measures - regulations ... sources, etc. A new book Paradise Regained: ...
... PHILADELPHIA People with the heritable disorder of ... to develop basal cell carcinoma of the skin may ... According to results of a placebo-controlled, randomized, double-blind, ... in inhibiting the development of basal cell carcinomas in ...
... plan to put two and two together in a study ... Two traits that impact corn will be examined by ... products at the farm level. Drought tolerance and aflatoxin ... Research scientists who have been awarded a $500,000 grant for ...
Cached Biology News:Global warming and other environmental dangers may be solved by unlikely source -- space technology 2Celebrex inhibited the burden of skin cancer in high-risk patients 2Genes for drought-tolerance, aflatoxin may mingle to boost corn production 2
... synthetic peptide whose sequence is from rat SCAMP 5. The ... - N(217) - Q - P - Q - T - ... - N - Y - T - Y - S - ... control experiments with the polyclonal antibody that reacts with this product ...
... of IgY) , After we receive your antigen ... the appropriate number of chickens and begin to ... collected (usually over a period of 3-5 days), ... total of four injections into the breast muscle. ...
... for which no antibody exists? Having difficulty generating ... a variety of pharmaceutical, biotech and academic researchers ... technology and expertise in antibody generation to work ... RabMAb development technology , High affinity and high ...
... Rapid-Screen cDNA Library Panels were designed for ... sets of PCRs to identify the desired ... performed in a 96-well "Master Plate," where ... clones. Having identified the positive well(s) by ...
Biology Products: